• Protein biomarkers making an impact in clinical trials for Atopic Dermatitis.

    DS Biopharma have announced in a press release that oral treatment with the immunomodulating, bioactive lipid, DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical trial. Protein data generated using Olink’s biomarker panels provided evidence of the favorable effect of the compound, based on the reversal of the AD molecular signature. For more details, please read the full press release. If you have any questions about this exciting development, please contact DS Biopharma directly.